Great Tree Pharmacy Co., Ltd.
TPEX:6469 Rapporto sulle azioni
Cap. di mercato: NT$23.3b
Aggiungi alla lista di controlloGreat Tree Pharmacy Crescita futura
Future criteri di controllo 2/6 Great Tree Pharmacy prevede che gli utili e i ricavi cresceranno rispettivamente di 15.4% e 12.8% all'anno. Si prevede che l'EPS crescerà di 12.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 20.8% in 3 anni.
Informazioni chiave
15.4%
Tasso di crescita degli utili
12.1%
Tasso di crescita dell'EPS
Consumer Retailing crescita degli utili 19.2% Tasso di crescita dei ricavi 12.8% Rendimento futuro del capitale proprio 20.8% Copertura analitica Low
Ultimo aggiornamento 11 Nov 2024
Aggiornamenti recenti sulla crescita futura
Consensus EPS estimates fall by 13% May 14
Consensus EPS estimates fall by 18% Aug 11
Price target increased by 7.6% to NT$324 Feb 24
Consensus forecasts updated Aug 30
Mostra tutti gli aggiornamenti
Third quarter 2024 earnings released: EPS: NT$1.27 (vs NT$1.26 in 3Q 2023) Nov 11
New minor risk - Shareholder dilution Aug 21
Second quarter 2024 earnings released: EPS: NT$1.29 (vs NT$1.29 in 2Q 2023) Aug 13
Great Tree Pharmacy Co., Ltd. to Report Q2, 2024 Results on Aug 09, 2024 Aug 02
Upcoming dividend of NT$3.60 per share Jul 03
Dividend of NT$3.60 announced Jun 13
Great Tree Pharmacy Co., Ltd. Announces Cash Dividend , Payable on July 31, 2024 Jun 13
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 18
Consensus EPS estimates fall by 13% May 14 Great Tree Pharmacy Co., Ltd. to Report Q1, 2024 Results on May 10, 2024 May 03
Less than half of directors are independent Apr 03
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 06 Great Tree Pharmacy Co., Ltd. announced a financing transaction
New minor risk - Shareholder dilution Dec 23
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 15
New major risk - Earnings quality Aug 12
Great Tree Pharmacy Co., Ltd. Announces Convener of Audit Committee Changes Aug 11
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 11
Consensus EPS estimates fall by 18% Aug 11
Upcoming dividend of NT$4.70 per share at 1.3% yield Jun 28
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Jun 07
Great Tree Pharmacy Co., Ltd. Announces Cash Dividend for the Year 2022, Payable on July 28, 2023 Jun 06
Great Tree Pharmacy Co., Ltd. Appoints Min-Hsiung Pan as Member of the Audit Committee and the Remuneration Committee Jun 02
Great Tree Pharmacy Co., Ltd. Elects Min-Hsiung Pan as Independent Director Jun 01
Now 23% undervalued May 12
Full year 2022 earnings: EPS misses analyst expectations Mar 01
Price target increased by 7.6% to NT$324 Feb 24
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 16
Less than half of directors are independent Nov 16
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 13
Now 20% undervalued Oct 26 Great Tree Pharmacy Co., Ltd. announced that it has received TWD 220 million in funding from Sugi Holdings Co.,Ltd. Sep 17
Great Tree Pharmacy Co., Ltd. announced that it expects to receive funding from Sugi Holdings Co.,Ltd. Sep 08
Consensus forecasts updated Aug 30
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 13
Investor sentiment improved over the past week Jul 11
Upcoming dividend of NT$2.57 per share Jun 22
Great Tree Pharmacy Co., Ltd. Announces Cash Dividend, Payable on July 21, 2022 Jun 15
Investor sentiment improved over the past week Jun 10
Less than half of directors are independent May 16
First quarter 2022 earnings released: EPS: NT$1.67 (vs NT$1.04 in 1Q 2021) May 14
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 28
Great Tree Pharmacy Co., Ltd. Approves Dividend Distribution for the Year Ended December 31, 2021 Feb 27
Great Tree Pharmacy Co., Ltd., Annual General Meeting, May 31, 2022 Feb 26
Investor sentiment improved over the past week Feb 24
Third quarter 2021 earnings released: EPS NT$1.51 (vs NT$0.66 in 3Q 2020) Nov 12
Investor sentiment deteriorated over the past week Sep 10
Investor sentiment improved over the past week Aug 24
Second quarter 2021 earnings released: EPS NT$2.20 (vs NT$0.86 in 2Q 2020) Aug 13
Investor sentiment improved over the past week Jul 23
Upcoming dividend of NT$0.99 per share Jul 15
Investor sentiment improved over the past week Jun 24
First quarter 2021 earnings released: EPS NT$1.34 (vs NT$0.92 in 1Q 2020) May 15
Investor sentiment improved over the past week Mar 24
There Are Reasons To Feel Uneasy About Great Tree Pharmacy's (GTSM:6469) Returns On Capital Mar 24
Great Tree Pharmacy Co., Ltd. Approves Dividend Distribution Mar 20
Great Tree Pharmacy Co., Ltd., Annual General Meeting, Jun 24, 2021 Mar 19
Full year 2020 earnings released: EPS NT$3.73 (vs NT$2.77 in FY 2019) Mar 19
New 90-day high: NT$101 Mar 12
Is Great Tree Pharmacy (GTSM:6469) A Risky Investment? Mar 03
Is Great Tree Pharmacy Co., Ltd.'s (GTSM:6469) Stock's Recent Performance A Reflection Of Its Financial Health? Feb 09
Great Tree Pharmacy's (GTSM:6469) Earnings Are Growing But Is There More To The Story? Jan 19
Did You Miss Great Tree Pharmacy's (GTSM:6469) 71% Share Price Gain? Dec 28
Should We Be Excited About The Trends Of Returns At Great Tree Pharmacy (GTSM:6469)? Dec 09
New 90-day high: NT$100.00 Nov 24
Third quarter 2020 earnings released: EPS NT$0.86 Nov 12
New 90-day high - NT$94.50 Aug 24
First half earnings released Aug 13
Previsioni di crescita degli utili e dei ricavi TPEX:6469 - Stime future degli analisti e dati finanziari passati (TWD Millions ) Data Ricavi Guadagni Flusso di cassa libero Liquidità dell'operazione Avg. Numero di analisti 12/31/2026 22,439 963 1,049 1,249 3 12/31/2025 20,119 826 763 1,123 3 12/31/2024 17,354 713 -536 1,020 1 9/30/2024 16,974 685 571 973 N/A 6/30/2024 16,690 681 998 1,378 N/A 3/31/2024 16,536 678 1,019 1,374 N/A 12/31/2023 16,144 666 564 890 N/A 9/30/2023 15,735 655 649 971 N/A 6/30/2023 15,294 661 108 433 N/A 3/31/2023 15,185 739 535 830 N/A 12/31/2022 14,565 700 911 1,227 N/A 9/30/2022 13,827 644 889 1,146 N/A 6/30/2022 13,124 580 1,164 1,441 N/A 3/31/2022 11,993 454 688 964 N/A 12/31/2021 11,281 407 823 1,078 N/A 9/30/2021 10,617 354 819 1,091 N/A 6/30/2021 9,954 295 820 1,042 N/A 3/31/2021 9,108 220 494 736 N/A 12/31/2020 8,641 194 477 728 N/A 9/30/2020 8,079 171 126 420 N/A 6/30/2020 7,540 163 -88 214 N/A 3/31/2020 7,137 156 -57 246 N/A 12/31/2019 6,602 136 -54 225 N/A 9/30/2019 6,170 134 108 341 N/A 6/30/2019 5,727 124 -2 246 N/A 3/31/2019 5,296 109 68 277 N/A 12/31/2018 4,901 106 -51 131 N/A 9/30/2018 4,503 104 17 180 N/A 6/30/2018 4,173 107 N/A 252 N/A 3/31/2018 3,889 107 N/A 147 N/A 12/31/2017 3,624 102 N/A 157 N/A 9/30/2017 3,420 96 N/A 62 N/A 6/30/2017 3,192 92 N/A 127 N/A 3/31/2017 2,983 90 N/A 64 N/A 12/31/2016 2,802 93 N/A 129 N/A 9/30/2016 2,615 101 N/A 107 N/A 6/30/2016 2,465 94 N/A 25 N/A 3/31/2016 2,317 91 N/A 76 N/A 12/31/2015 2,160 77 N/A -3 N/A 9/30/2015 2,047 83 N/A 11 N/A 6/30/2015 1,919 79 N/A -14 N/A 3/31/2015 1,774 82 N/A -17 N/A 12/31/2014 1,662 96 N/A 95 N/A 9/30/2014 1,473 75 N/A 55 N/A 6/30/2014 1,349 80 N/A 74 N/A 3/31/2014 1,242 74 N/A 64 N/A 12/31/2013 1,136 68 N/A 55 N/A
Mostra di più
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di 6469 ( 15.4% all'anno) è superiore al tasso di risparmio ( 1.1% ).
Guadagni vs Mercato: Si prevede che gli utili di 6469 ( 15.4% all'anno) cresceranno più lentamente rispetto al mercato TW ( 20.2% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di 6469 cresceranno, ma non in modo significativo .
Ricavi vs Mercato: Si prevede che il fatturato di 6469 ( 12.8% all'anno) crescerà più lentamente rispetto al mercato TW ( 12.9% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di 6469 ( 12.8% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di 6469 sarà elevato tra 3 anni ( 20.8 %)
Scoprire le aziende in crescita Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}